A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients with genetically ascertained ULD [Unverricht-Lundborg disease]
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Brivaracetam (Primary)
- Indications Unverricht-Lundborg syndrome
- Focus Registrational; Therapeutic Use
- Sponsors UCB; UCB Pharma SA
- 15 Dec 2015 Results from this and other trial (see profile 29358) published in the Epilepsia
- 18 Aug 2009 Actual patient number (56) added as reported by ClinicalTrials.gov.
- 05 Feb 2008 Status changed from in progress to completed according to ClinicalTrials.gov.